Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siSIRT3 is a small interfering RNA (siRNA) designed to silence the expression of Sirtuin 3 (SIRT3), a mitochondrial NAD+-dependent deacetylase. SIRT3 is a member of the sirtuin family (Class III histone deacetylases) and is primarily localized in the mitochondria, where it regulates metabolic processes, oxidative stress, and cell survival. In the context of oncology, particularly melanoma, SIRT3 has been identified as having pro-proliferative functions. siSIRT3 is utilized in preclinical research to evaluate the therapeutic potential of SIRT3 inhibition in models such as BrafV600E/PtenNULL mice and patient-derived xenografts (PDX). Research findings suggest that while siSIRT3 can reduce tumor growth and metastatic lung nodules, its efficacy as a monotherapy may be limited, indicating that the concomitant inhibition of multiple sirtuins (such as SIRT1 and SIRT3) might be a more effective strategy for melanoma management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siSIRT3.